₹1,799
▲ +10.55 +0.59%
17 Jul 2026
NSE Listed
ASM 4Venus Remedies Limited (VENUSREM)
Volume: 19,968Avg Vol 1W: 46,088.6Avg Vol 1M: 60,732.5552W Range:₹424₹2,044.3
Key Ratios
Checked 3h agoMarket Cap₹2,534 Cr
Current Price₹1,799
Previous Close₹1,788.45
High / Low (52w)₹2,044.3 / ₹424
Volume19,968
Avg Vol (1W)46,088.6
Avg Vol (1M)60,732.55
Stock P/E7.62
Book Value₹441.01
Dividend Yield—
ROE8.1%
ROA—
Revenue (TTM)₹669 Cr
Revenue Growth—
Profit Margin—
Total Debt₹0 Cr
Shares Outstanding—
Face Value₹10
EPS (TTM)₹39.32
P/B0.68
Debt / Equity0.04
50 DMA₹1,595.06
200 DMA₹954.33
Day change+0.59%
SurveillanceASM 4 (as of 2026-07-15)
Price Chart
₹1,799▲ 225.43% · 1Y
2025-07-172026-07-16
20-day avg volume: 61K shares
Pros
- Company is almost debt-free.
- Stock trades below its book value.
Cons
- Revenue fell 39% YoY.
- Company is loss-making at the latest annual result.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹109 Cr | ₹170 Cr | ₹177 Cr | ₹195 Cr | ₹137 Cr | ₹193 Cr | ₹180 Cr | ₹259 Cr |
| EBITDA | ₹7 Cr | ₹9 Cr | ₹15 Cr | ₹31 Cr | ₹13 Cr | ₹27 Cr | ₹33 Cr | ₹62 Cr |
| Net Profit | ₹1 Cr | ₹4 Cr | ₹20 Cr | ₹21 Cr | ₹10 Cr | ₹20 Cr | ₹26 Cr | ₹48 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹375 Cr | ₹328 Cr | ₹345 Cr | ₹568 Cr | ₹608 Cr | ₹566 Cr | ₹613 Cr | ₹669 Cr |
| EBITDA | ₹8 Cr | ₹5 Cr | ₹14 Cr | ₹38 Cr | ₹37 Cr | ₹38 Cr | ₹45 Cr | ₹62 Cr |
| Net Profit | ₹-31 Cr | ₹-29 Cr | ₹-10 Cr | ₹62 Cr | ₹41 Cr | ₹27 Cr | ₹28 Cr | ₹45 Cr |
| EPS | -24.87 | -23.16 | -8.1 | 50.04 | 30.86 | 19.88 | 21.31 | 33.9 |
Balance Sheet
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹751 Cr | ₹733 Cr | ₹644 Cr | ₹556 Cr | ₹580 Cr | ₹601 Cr | ₹627 Cr | ₹716 Cr |
| Total Liabilities | ₹389 Cr | ₹400 Cr | ₹320 Cr | ₹156 Cr | ₹139 Cr | ₹141 Cr | ₹139 Cr | ₹155 Cr |
| Equity | ₹362 Cr | ₹333 Cr | ₹323 Cr | ₹400 Cr | ₹440 Cr | ₹460 Cr | ₹488 Cr | ₹561 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹31 Cr | ₹45 Cr | ₹63 Cr | ₹108 Cr | ₹41 Cr | ₹37 Cr | ₹53 Cr | ₹101 Cr |
| Investing | ₹-11 Cr | ₹-11 Cr | ₹-5 Cr | ₹56 Cr | ₹-17 Cr | ₹-51 Cr | ₹-7 Cr | ₹-76 Cr |
| Financing | ₹-39 Cr | ₹-35 Cr | ₹-73 Cr | ₹-162 Cr | ₹-9 Cr | ₹-1 Cr | ₹-1 Cr | ₹-1 Cr |
| Free Cash Flow | ₹18 Cr | ₹45 Cr | ₹63 Cr | ₹108 Cr | ₹41 Cr | ₹37 Cr | ₹53 Cr | ₹101 Cr |
Shareholding
Promoter 41.76% Institutions 4% Public 54.24%
Efficiency & Working Capital
ROCE19.8%
Interest Coverage862.1
Dividend Payout—
Debtor Days63 d
Inventory Days57 d
Payable Days52 d
Cash Conversion Cycle68 d
Working Capital Days120 d
Shareholding Details
As of 2026-03-31
Promoter41.8%
FII2.8%
DII1.2%
Institutions4%
Public54.2%
Promoter Pledge0%
No. of Shareholders18,403
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 41.8% | 41.8% | 41.8% | 41.8% | 41.8% | 41.8% | 41.8% | 41.8% | 41.8% | 41.8% | 41.8% | 41.8% |
| FIIs | 1% | 1% | 1.6% | 1.5% | 1.1% | 1.2% | 1.1% | 1.3% | 2.2% | 1.9% | 2.3% | 2.8% |
| DIIs | 0.2% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0% | 0% | 0.1% | 0.7% | 1% | 1.2% |
| Public | 57.1% | 57.1% | 56.5% | 56.6% | 57% | 56.9% | 57.1% | 56.9% | 55.9% | 55.6% | 55% | 54.2% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 20,498 | 19,267 | 19,560 | 19,913 | 19,614 | 19,557 | 19,771 | 19,982 | 19,307 | 17,725 | 18,606 | 18,403 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Sunev Pharma Solutions Private Limited | Shareholding of Promoter and Promoter Group | 17.2% | 23,00,000 |
| Pawan Chaudhary | Shareholding of Promoter and Promoter Group | 12.8% | 17,13,946 |
| Manu Chaudhary | Shareholding of Promoter and Promoter Group | 11.7% | 15,68,000 |
| Tikri Partners Llp | Public Shareholding | 2% | 2,62,700 |
| Rajni Tarun Jain | Public Shareholding | 1.4% | 1,90,000 |
| K.b.shekar | Public Shareholding | 1.4% | 1,90,000 |
| Acadian Emerging Markets Micro-cap Equity Master Fund | Public Shareholding | 1.1% | 1,47,501 |
| Nisarg Ajaykumar Vakharia | Public Shareholding | 1.1% | 1,40,000 |
| Peeyush Jain | Shareholding of Promoter and Promoter Group | 0% | 50 |
| Akshansh Chaudhary | Shareholding of Promoter and Promoter Group | 0% | 1 |
| Ashutosh Jain | Shareholding of Promoter and Promoter Group | 0% | 0 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Pawan Chaudhary | 0 | 0% | 2026-03-31 |
| Manu Chaudhary | 0 | 0% | 2026-03-31 |
| Peeyush Jain | 0 | 0% | 2026-03-31 |
| Akshansh Chaudhary | 0 | 0% | 2026-03-31 |
| Ashutosh Jain | 0 | 0% | 2026-03-31 |
| Sunev Pharma Solutions Private Limited | 0 | 0% | 2026-03-31 |
| Acadian Emerging Markets Micro-cap Equity Master Fund | 0 | 0% | 2026-03-31 |
| K.b.shekar | 0 | 0% | 2026-03-31 |
| Nisarg Ajaykumar Vakharia | 0 | 0% | 2026-03-31 |
| Rajni Tarun Jain | 0 | 0% | 2026-03-31 |
| Tikri Partners Llp | 0 | 0% | 2026-03-31 |
| Pawan Chaudhary | 0 | 0% | 2025-12-31 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Pawan Chaudhary | Chairman / WTD / Managing Director / CFO | 2025 |
| Manu Chaudhary | Whole Time Director & JMD | 2025 |
| Peeyush Jain | Whole Time Director / Deputy Managing Director | 2025 |
| Ashutosh Jain | E D & Wholetime Director | 2025 |
| Akshansh Chaudhary | Whole Time Director & CTO | 2025 |
| Navdeep Sud | Independent Director | 2025 |
| Savita Gupta | Independent Director | 2025 |
| Pravindra Singh Chauhan | Independent Non Exe. Director | 2025 |
| Nps Monga | Independent Non Exe. Director | 2025 |
| Anil Kumar | Independent Non Exe. Director | 2025 |
| Jagdish Chander Sharma | Independent Non Exe. Director | 2025 |
| Neha Arora | Company Sec. & Compli. Officer | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Pharmaceutical Formulation | ₹0 Cr | — |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹10 | 20 | 13 | 13 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-07-20 | Board Meetings | — |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 30 | 0 | 0 | 5 | 15 | 51 |
| 2025 | 0 | 0 | 0 | 0 | -22 | -22 |
| 2025 | 0 | 0 | 0 | 0 | 4 | 4 |
Insider / Designated-Person Trades
3 recent disclosure(s)
PAWAN CHAUDHARYAcquisition · 1,26,946
PAWAN CHAUDHARY RevisedAcquisition · 6,00,000
MANU CHAUDHARY RevisedAcquisition · 4,25,000
Company Information
Incorporated1989
ChairmanPawan Chaudhary
AuditorJ K Jain & Associates
Investor Email[email protected]; complianceoff
📍 S C No 857 Cabin No 10 2nd Flr, N A C Manimajra, Chandigarh, Chandigarh, 160101
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Veekayem Fash & App Ltd.Veljan Denison Ltd.Vels Film International LimitedVenky S (India) LimitedVentive Hospitality Ltd.Venus Pipes & Tubes Ltd.Vera Synthetic LimitedVeranda Learning Sol Ltd.Veritaas Advertising Ltd.Vertexplus Technologies LimitedVertis Infrastructure TstVertoz LimitedAll “V” stocks →
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search